61477-96-1

• 常用中文名：哌拉西林
• 常用英文名：Piperacillin
• CAS号：61477-96-1
• 分子式：C₂₃H₂₇N₅O₇S
• 分子量：517.555
• 相关类别： 原料药 抗生素类药物 青霉素类药
• 发布时间：2018-09-10 19:10:20
• 更新时间：2026-07-02 14:16:21
• 【用途一】
  具有广谱抗菌作用，对革兰阳性和阴性菌均有良好的抗菌活性
  【用途二】
  该品为广谱低毒的第三代半合成青霉素，该品的杀菌作用优于现在的半合青霉素。

名称

• 中文名: 哌拉西林
• 英文名: piperacillin
• 中文别名: 哌拉西林-D5,(N-CD2CD3); 哌嗪西林溶液, 100PPM; (2S,5R,6R)-6-((R)-2-(4-乙基-2,3-二氧代哌嗪-1-甲酰胺基)-2-苯基乙酰胺基)-3,3-二甲基-7-氧代-4-硫代-1-氮杂双环[3.2.0]庚烷-2-甲酸; (2S,5R,6R)-3,3-二甲基-6-[(4-乙基-2,3-二氧代-1-哌嗪甲酰氨基)苯乙酰氨基]-7-氧代-4-硫杂-1-氮杂双环[3.2.0]庚烷-2-甲酸; 哌拉西林(酸)一水合物; 哌拉西林酸; 哌拉西林61-1; PIPERACILLIN 哌拉西林; 哌拉西林相关杂质; 哌拉西林-[D5]/精确称量; 哌拉西林,10 MM DMSO 溶液; 哌拉西林/哌拉西林酸; 哌拉西林-D5(N-乙基-D5); 氧哌嗪青霉素酸; (2S,5R,6R)-6-((R)-2-(4-乙基-2,3-二氧代哌嗪-1-甲酰胺基)-2-苯基乙酰胺基)-3,3-二甲基-7-氧代-4-硫杂-1-氮杂双环[3.2.0]庚烷-2-羧酸; 哌拉西林, 含量测定; (2S,5R,6R)-6-((R)-2-(4-乙基-2,3-二氧杂哌嗪-1-羧酰胺基)-2-苯基乙酰胺基)-3,3-二甲基-7-氧代-4-硫-1-氮杂双环[3.2.0]庚烷-2-羧酸(哌拉西林杂质); 氧哌嗪青霉素; 哌拉西林PIPERACILLIN; PIPERACILLIN 标准品; 氘5-哌拉西林; 氧哌嗪青霉素/氧哌嗪青霉素酸/(2S,5R,6R)-3,3-二甲基-6-[(4-乙基-2,3-二氧代-1-哌嗪甲酰氨基)苯乙酰氨基]-7-氧代-4-硫杂-1-氮杂双环[3.2.0]庚烷-2-甲酸; 匹拉西林; 哌拉西林(酸)一水; 哌拉西林-D5; 哌拉西林-D5(苯基-D5); 哌啶素
• 英文别名: Piperacillin, >=; 4-Thia-1-azabicyclo[3.2.0]htane-2-cboxylic acid, 6-[[[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2a,5a,6b(S*)]]; 4-Thia-1-azabicyclo[3.2.0]htane-2-cboxylic acid,6-[[(2R)-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R); 4-Thia-1-azabicyclo[3.2.0]htane-2-cboxylic acid, 6-[[(2R)-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, (2S,5R,6R)- (9CI); Pipracil //BP; PIPC; (2S,5R,6R)-6-((R)-2-(4-Ethyl-2,3-Dioxopiperazine-1-cboxamido)-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]htane-2-cboxylic acid; 4-thia-1-azabicyclo(3.2.0)htane-2-cboxylicacid,3,3-dimethyl-6-(((((4-ethy; MFCD00917471; PIPERACILLIN; Pipercillin; Piperacilin Acid; [2S-[2α,5α,6β(S*)]]-6-[[[[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]htane-2-cboxylic acid; (2R,5R,6R)-6-{[(2R)-2-{[(4-Ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; 6-[[[[(4-Ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid; Piperacillin-d5 (N-ethyl-d5); Piperacillin solution,100ppm; Piperacillin anhydrous; Pipraci; 4-Thia-1-azabicyclo[3.2.0]htane-2-cboxylicacid,6-[[(2R)-2-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]-2-phenylacetyl]amino]-3,3-diMethyl-7-oxo-,(2S,5R,6R); C14034; PIPERACILLIN (CRM STANDD); D5-Piperacillin; Piperacillin, in methanol; Piperacillin (base and/or unspecified salts); [2S-[2alpha,5alpha,6beta(S*)]]-6-[[[[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]htane-2-cboxylic acid; PIPERACILLIN SODIUM; (N-CD2CD3); (2S,5R,6R)-6-[[(2R)-[[(4-Ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-Thia-1-azabicyclo[3.2.0]htane-2-cboxylic acid; 6-{[{[(4-Ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino}(phenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid; (2S,5R,6R)-6-[[(2R)-2-[[(4-Ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]htane-2-cboxylic acid monohydrate; Piperacillin (Acid) Monohydrate; 6α-[[(R)-(4-Ethyl-2,3-dioxo-1-piperazinylcbonylamino)phenylacetyl]amino]penicillanic acid; Piperacillin-d5 (phenyl-d5); Piperacillin-D5, (N-CD2CD3); 6-(d-(-)-alpha-(4-ethyl-2,3-dioxo-1-piperazinecboxamido)phenylacetamido)pe; (2S,5R,6R)-6-((R)-2-(4-Ethyl-2,3-dioxopiperazine-1-cboxamido)-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]htane-2-cboxylic acid (Piperacillin Impurity); (2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxo-piperazine-1-carbonyl)amino]-2-phenyl-acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]htane-2-cboxylic acid; (2S,5R,6R)-6-((R)-2-(4-Ethyl-2,3-dioxo-piperazine-1-cboxcboxamido)-2-phenyl-acetcboxcboxcboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]htane-2-cboxylic acid; Piperacil; EINECS 262-811-8; PIPERACILLIN NA; 3-dioxo-1-piperazinyl)carbonyl)amino)phenylacetyl)amino)-7-oxo-l-(2s-(2-al; PiperacillinQ: What is Piperacillin Q: What is the CAS Number of Piperacillin Q: What is the storage condition of Piperacillin; 6α-[[(R)-α-Oxo-β-[[(2,3-dioxo-4-ethyl-1-piperazinyl)carbonyl]amino]phenethyl]amino]penicillanic acid; PIPERACILLIN P(CRM STANDD); piperacillin, 10 mM in DMSO; PIPERACILLIN (NON-STERILE API); (2S,5R,6R)-6-((R)-2-(4-ethyl-2,3-dioxopiperazine-1-cboxamido)-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]htane-2-cboxylic acid hydrate; PIPERAILLIN; Pipracil

物化性质

• 密度: 1.5±0.1 g/cm3
• 熔点: 139-140ºC
• 分子式: C₂₃H₂₇N₅O₇S
• 分子量: 517.555
• 精确质量: 517.163147
• PSA: 181.73000
• LogP: 1.88
• 外观性状: 白色结晶粉末
• 折射率: 1.678
• 储存条件: Hygroscopic, -20°C Freezer, Under Inert Atmosphere

生物活性

• 描述: 哌拉西林是一种半合成青霉素。哌拉西林对革兰氏阳性和革兰氏阴性需氧菌和厌氧菌具有广谱活性。哌拉西林对产生β-内酰胺酶的微生物的活性高于其他青霉素[1]。
• 相关类别:
  研究领域 >> 感染
  信号通路 >> 抗感染 >> 细菌
• 参考文献:

  [1]. B. Holmes, et al. A Review of its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Use.

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : XH8952200 CHEMICAL NAME : 4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-6-(((((4-ethyl-2,3-dioxo- 1-piperazinyl)carbonyl)amino)phenylacetyl)amino)-7-ox o-, (2S-(2-alpha,5-alpha,6-beta(S*)))- CAS REGISTRY NUMBER : 61477-96-1 LAST UPDATED : 199706 DATA ITEMS CITED : 2 MOLECULAR FORMULA : C23-H27-N5-O7-S MOLECULAR WEIGHT : 517.61 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 5 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : YKKZAJ Yakugaku Zasshi. Journal of Pharmacy. (Nippon Yakugakkai, 2-12-15 Shibuya, Shibuya-ku, Tokyo 150, Japan) No.1- 1881- Volume(issue)/page/year: 97,987,1977 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X5651 No. of Facilities: 148 (estimated) No. of Industries: 1 No. of Occupations: 4 No. of Employees: 9665 (estimated) No. of Female Employees: 8470 (estimated)

安全

• 危害码 (欧洲): Xi
• 风险声明 (欧洲): 42/43
• 安全声明 (欧洲): 36/37
• 海关编码: 2941101900

合成路线

59703-84-3 ~% 61477-96-1

文献：Journal of Pharmaceutical Sciences, , vol. 99, # 5 p. 2333 - 2342

上下游产品

上游产品  1
59703-84-3
下游产品  2
59703-84-3 89785-84-2

制备

【方法一】
可用β-羟乙胺为起始原料，经溴化、胺化、环合、酰氯化后，制得铡链EPCP。然后与6-APA（6-氨基青霉烷酸）缩合制得哌拉西林。

海关

海关编码	2941101900